SCHEMBL2226110

SCHEMBL2226110

Clc1ccc(Nc2cccc(-c3cnc(Cl)o3)n2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.44
KDR P35968 1/20 0.42
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
MAPT P10636 5/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
KDM4E B2RXH2 4/20 0.41
NFKB1 P19838 3/20 0.41
NFKB2 Q00653 3/20 0.41
RELA Q04206 3/20 0.41
XBP1 P17861 1/20 0.41
AHR P35869 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPK1 P28482 1/20 0.36
TSHR P16473 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229276 0.84 KDR (0.46) SLC2A1KDRMEN1KMT2AMAPT
SCHEMBL2352796 0.81 GRM5 (0.41) SLC2A1KDRMEN1KMT2AMAPT
SCHEMBL2225415 0.80 KARS1 (0.45) KDRMEN1KMT2AKDM4EHSD17B10
SCHEMBL4898748 0.80 SLC2A1 (0.50) SLC2A1KDRMEN1KMT2AMAPT
SCHEMBL2226495 0.79 MEN1 (0.39) SLC2A1KDRMEN1KMT2AMAPT
SCHEMBL14673765 0.78 ABL1 (0.39)
SCHEMBL4903020 0.77 SLC2A1 (0.51) SLC2A1KDRMEN1KMT2AMAPT
SCHEMBL2227009 0.77 KARS1 (0.58) SLC2A1KDRMEN1KMT2ANPC1
SCHEMBL4892301 0.76 SLC2A1 (0.44) SLC2A1KDRMEN1KMT2AMAPT
SCHEMBL14680970 0.76 CCNT1 (0.36) SLC2A1KDRMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2523952-B1 OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2015-03-04 EP disclosed
US-8962665-B2 Thiazole and oxazole kinase inhibitors AB SCIENCE (FR) 2015-02-24 US disclosed
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2013-02-07 US disclosed
CN-102812022-A Thiazole and oxazole kinase inhibitors AB SCIENCE 2012-12-05 CN disclosed
EP-2523952-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB Science (FR) 2012-11-21 EP disclosed
WO-2011086085-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS AB SCIENCE (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130035331-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SYK, LTK, MERTK SLC2A1 2324/4885KDR 79/4885MEN1 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.